Suppr超能文献

20S蛋白酶体与TMC-95A复合物的晶体结构:一种非共价蛋白酶体抑制剂

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.

作者信息

Groll M, Koguchi Y, Huber R, Kohno J

机构信息

Max-Planck-Institut für Biochemie, Martinsried, D-82152, Germany.

出版信息

J Mol Biol. 2001 Aug 17;311(3):543-8. doi: 10.1006/jmbi.2001.4869.

Abstract

The 20 S proteasome core particle (CP), a multicatalytic protease, is involved in a variety of biologically important processes, including immune response, cell-cycle control, metabolic adaptation, stress response and cell differentiation. Therefore, selective inhibition of the CP will be one possible way to influence these essential pathways. Recently, a new class of specific proteasome inhibitors, TMC-95s, was investigated and we now present a biochemical and crystallographic characterisation of the yeast proteasome core particle in complex with the natural product TMC-95A. This unusual heterocyclic compound specifically blocks the active sites of CPs non-covalently, without modifying the nucleophilic Thr1 residue. The inhibitor is bound to the CP by specific hydrogen bonds with the main-chain atoms of the protein. Analysis of the crystal structure of the complex has revealed which portions of TMC-95s are essential for binding to the proteasome. This will form the basis for the development of synthetic selective proteasome inhibitors as promising candidates for anti-tumoral or anti-inflammatory drugs.

摘要

20S蛋白酶体核心颗粒(CP)是一种多催化蛋白酶,参与多种重要的生物学过程,包括免疫反应、细胞周期调控、代谢适应、应激反应和细胞分化。因此,选择性抑制CP将是影响这些重要途径的一种可能方式。最近,研究了一类新型的特异性蛋白酶体抑制剂TMC-95s,我们现在展示了与天然产物TMC-95A结合的酵母蛋白酶体核心颗粒的生化和晶体学特征。这种不同寻常的杂环化合物通过非共价方式特异性地阻断CP的活性位点,而不修饰亲核性的Thr1残基。该抑制剂通过与蛋白质主链原子形成特定的氢键与CP结合。对复合物晶体结构的分析揭示了TMC-95s的哪些部分对于与蛋白酶体结合至关重要。这将为开发合成选择性蛋白酶体抑制剂奠定基础,这些抑制剂有望成为抗肿瘤或抗炎药物的候选物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验